home / stock / dtil / dtil articles
Shares of Zscaler, Inc. (NASDAQ: ZS) shares fell sharply during Friday’s session following second-quarter results. Zscaler posted better-tha...
TG Therapeutics Inc (NASDAQ: TGTX) reported preliminary BRIUMVI U.S. net product sales for Q4 and FY23. TGTX expects BRIUMVI U.S. net pro...
Precision BioSciences, Inc. (NASDAQ: DTIL) shares are trading higher Tuesday after the company announced it has signed a licensing agreement with T...
Gainers Femasys Inc. (NASDAQ: FEMY) shares rose 201% to $1.00 in pre-market trading after the company received FDA 510(k) clearance for FemaSeed, ...
News, Short Squeeze, Breakout and More Instantly...
Precision BioSciences Inc. Company Name:
DTIL Stock Symbol:
NASDAQ Market:
0.18% G/L:
$5.33 Last:
69,382 Volume:
$5.49 Open:
$5.33 Close:
Precision BioSciences Inc. Website:
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS ® platform to develop in vivo gene editing therapies, including gene elimination, gene insertion, and gene excision programs, today announced that management will prese...
Nu Ride Inc. - Class A (NRDE) is expected to report for quarter end 2024-12-31 Dalrada Financial Corp. (DFCO) is expected to report for quarter end 2024-12-31 HilleVax Inc. (HLVX) is expected to report $-0.38 for Q4 2024 Chewy Inc. Class A (CHWY) is expected to report $0.03 for Q4 202...
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies, including gene elimination, gene insertion, and gene excision programs, today announced that it will publish financ...